For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
5
views
58
references
 Top references
cited by
3
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      31
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Great debate: in patients with decompensated heart failure, acetazolamide in addition to loop diuretics is the first choice

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Graphical Abstract

          Graphical abstract

          Key points in favour or against the addition of acetazolamide to loop diuretics as the first choice in patients with decompensated heart failure. Abbreviations: AHF, acute heart failure; HCTZ, hydrochlorothiazide; HHF, hospitalization for heart failure; SGLT2i, sodium–glucose cotransporter 2 inhibitor; WRF, worsening renal function.

          Related collections

          Most cited references58

          • Record: found
          • Abstract: not found
          • Article: not found

          2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

          Theresa A McDonagh, Marco Metra, Marianna Adamo … (2021)
          Article 0 comments Cited 2833 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

            John J.V. McMurray, Scott D. Solomon, Silvio E Inzucchi … (2020)
            In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.
            Article 0 comments Cited 1951 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

              Milton Packer, Stefan D. Anker, Javed Butler … (2020)
              Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction.
              Article 0 comments Cited 1547 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Wilfried Mullens
                Paul Christian Schulze:
                ORCID: https://orcid.org/0000-0001-9442-7141
                Julian Westphal
                Jürgen Bogoviku
                Johann Bauersachs:
                ORCID: https://orcid.org/0000-0002-9341-117X
                Journal
                Journal ID (nlm-ta): Eur Heart J
                Journal ID (iso-abbrev): Eur Heart J
                Journal ID (publisher-id): eurheartj
                Title: European Heart Journal
                Publisher: Oxford University Press (US )
                ISSN (Print): 0195-668X
                ISSN (Electronic): 1522-9645
                Publication date Collection: 21 June 2023
                Publication date (Electronic): 19 May 2023
                Publication date PMC-release: 19 May 2023
                Volume: 44
                Issue: 24 , Focus Issue on Heart Failure and Cardiomyopathies
                Pages: 2159-2169
                Affiliations
                Ziekenhuis Oost-Limburg, Genk, Belgium and Hasselt University , Diepenbeek/Hasselt, Belgium
                Department of Internal Medicine I, Cardiology, Angiology and Intensive Medical Care, University Hospital Jena , Jena, Germany
                Department of Internal Medicine I, Cardiology, Angiology and Intensive Medical Care, University Hospital Jena , Jena, Germany
                Department of Internal Medicine I, Cardiology, Angiology and Intensive Medical Care, University Hospital Jena , Jena, Germany
                Department of Cardiology and Angiology, Hannover Medical School , Hannover, Germany
                Department of Cardiology and Angiology, Hannover Medical School , Hannover, Germany
                Ziekenhuis Oost-Limburg, Genk, Belgium and Hasselt University , Diepenbeek/Hasselt, Belgium
                Department of Internal Medicine I, Cardiology, Angiology and Intensive Medical Care, University Hospital Jena , Jena, Germany
                Department of Internal Medicine I, Cardiology, Angiology and Intensive Medical Care, University Hospital Jena , Jena, Germany
                Department of Internal Medicine I, Cardiology, Angiology and Intensive Medical Care, University Hospital Jena , Jena, Germany
                Author notes
                Corresponding author. Tel: +49 511 532 3841, Fax: +49 511 532 5412, E-mail: bauersachs.johann@ 123456mh-hannover.de

                Wilfried Mullens and Paul Christian Schulze contributed equally.

                Conflict of interest W.M. received honoraria for lectures from Medtronic, Abbott, Novartis, Vifor Pharma, Astra Zeneca, Boehringer Ingelheim, and Pfizer, not related to this article. P.C.S. received honoraria for lectures/consulting from Novartis, Vifor, Bayer, Pfizer, Boehringer Ingelheim, AstraZeneca, Cardior, BMS, Abiomed, Pharmacosmos, and Amgen, not related to this article, and research support for the department from Boehringer Ingelheim, Edwards, and Abiomed, not related to this article. J.W. and Jü.B. have no conflicts of interest related to this article. Jo.B. received honoraria for lectures/consulting from Novartis, Vifor, Bayer, Pfizer, Boehringer Ingelheim, AstraZeneca, Cardior, CVRx, BMS, Amgen, Corvia, Norgine, Edwards, and Roche, not related to this article, and research support for the department from Zoll, CVRx, Abiomed, Norgine, and Roche, not related to this article.

                Author information
                https://orcid.org/0000-0001-9442-7141
                https://orcid.org/0000-0002-9341-117X
                Article
                Publisher ID: ehad266
                DOI: 10.1093/eurheartj/ehad266
                PMC ID: 10290873
                PubMed ID: 37207453
                SO-VID: 0934d1a9-7cdb-4e84-8437-1ae3280df19c
                Copyright © © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
                License:

                This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ( https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                Page count
                Pages: 11
                Funding
                Funded by: Deutsche Forschungsgemeinschaft, doi 10.13039/501100001659;
                Award ID: KFO 311
                Categories
                Subject: Great Debate
                Subject: AcademicSubjects/MED00200

                ScienceOpen disciplines: Cardiovascular Medicine
                Keywords: acute heart failure,diuretic therapy,acetazolamide,sglt2 inhibitors
                Data availability:
                ScienceOpen disciplines: Cardiovascular Medicine
                Keywords: acute heart failure, diuretic therapy, acetazolamide, sglt2 inhibitors

                Comments

                Comment on this article

                scite_

                Similar content31

                See all similar

                Cited by3

                See all cited by

                Most referenced authors1,368

                See all reference authors